Abstract
Interleukin (IL)-32 is a newly identified cytokine in humans and primates. It has been established that IL-32 may antagonize cancer growth. However, to the best of our knowledge, the direct effect of IL-32 on breast cancer cell growth has not yet been investigated. In addition, rodents lack the expression of IL-32; hence, the effects of IL-32 on breast cancer xenografts in nude mice have not been studied. The present study aimed to examine the potential regulatory effects of IL-32 on breast cancer cells in nude mice. The effects of IL-32 on tumor cell growth in cell cuture and a tumor xenograft model were investigated, as well as the effects of IL-32 on apoptosis. The effects of IL-32 on cell proliferation and apoptosis were investigated by MTT assay and TUNEL staining, respectively. The results revealed that IL-32 increases the proliferation rate of cancer cells and decreases the rate of apoptosis, In addition, IL-32 was found to enhance the growth of tumor xenografts in vivo. In summary, IL-32 may represent a useful therapeutic target for human breast cancer.
Highlights
Interleukin (IL)‐32, or NK4, is a novel cytokine which was originally isolated from activated T cells
Treatment of lymphocytes with IL‐32 may induce the expression of different cytokines, including tumor necrosis factor (TNF)‐α or IL‐8, which have been found to be involved in multiple inflammatory processes and cancer progression
To the best of our knowledge, the current study is the first to characterize the effects of IL‐32 on cancer cells directly; on breast cancer cells
Summary
This animal study has been approved by the Animal Research Ethics Committee of Xiangya Hospital, Central South University (Changsha, China). All procedures requiring animal manipulation followed the animal experiment guidelines of the Animal Center of Central South University. The approval number of this project is CSU3009‐2011‐BC009
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
